Go Pro

Q32 Bio (QTTB) 10K Form and Latest SEC Filings 2026

Q32 Bio logo
$15.60 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$15.75 +0.15 (+0.96%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Q32 Bio SEC Filings & Recent Activity

Q32 Bio (NASDAQ:QTTB) has submitted 404+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Q32 Bio's financial statements. The most recent filing was a Form 10-Q submitted on August 5, 2026.

Form 4
Q32 Bio Inc. Reports Ownership Change on Jul. 21, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Q32 Bio Files Current Report on Aug. 5, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Q32 Bio Files Quarterly Report on Aug. 5, 2026

The 10-Q contains Q32 Bio's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Q32 Bio SEC Filing History

Browse Q32 Bio's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
08/05/2026 6:09 AM
Q32 Bio (1661998) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/05/2026 6:02 AM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2026 3:05 PM
Opaleye Management Inc. (1595855) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13G/A
07/21/2026 7:37 PM
Iwicki Mark T (1415537) Reporting
Q32 Bio (1661998) Issuer
Form 4/A
07/21/2026 7:39 PM
LAPORTE KATHLEEN (1196201) Reporting
Q32 Bio (1661998) Issuer
Form 4/A
07/21/2026 7:39 PM
Lundberg Sven Ante (1682126) Reporting
Q32 Bio (1661998) Issuer
Form 4/A
07/21/2026 7:40 PM
Q32 Bio (1661998) Issuer
TZIANABOS ARTHUR (1586226) Reporting
Form 4/A
07/21/2026 7:22 PM
Q32 Bio (1661998) Issuer
Thistle Mary (1317917) Reporting
Form 4/A
07/21/2026 7:24 PM
GRAYZEL DAVID S. (1732786) Reporting
Q32 Bio (1661998) Issuer
Form 4/A
07/21/2026 7:25 PM
Manke Isaac (1622769) Reporting
Q32 Bio (1661998) Issuer
Form 4/A
07/21/2026 7:25 PM
Q32 Bio (1661998) Issuer
Xu Diyong (1995088) Reporting
Form 4/A
07/20/2026 8:25 PM
Kalowski Lee (1618273) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/20/2026 8:27 PM
Morrison Jodie Pope (1618247) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/20/2026 8:31 PM
Q32 Bio (1661998) Issuer
Violette Shelia M. (2016144) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/20/2026 8:32 PM
ORBIMED ADVISORS LLC (1055951) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13D/A
07/17/2026 3:14 PM
Q32 Bio (1661998) Filer
Form S-3
Registration statement under Securities Act of 1933  
07/15/2026 4:11 PM
Q32 Bio (1661998) Filer
Form 424B5
07/15/2026 4:18 PM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/13/2026 11:15 PM
Q32 Bio (1661998) Filer
Form EFFECT
07/13/2026 3:47 PM
Q32 Bio (1661998) Filer
Form 424B5
07/13/2026 7:39 AM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/13/2026 6:09 AM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/10/2026 3:34 PM
Boxer Capital Management, LLC (2018299) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13G
07/06/2026 6:20 PM
Carlyle Group Inc. (1527166) Filed by
Carlyle Group Inc. (1527166) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13G/A
06/25/2026 3:11 PM
Q32 Bio (1661998) Filer
Form S-3
Registration statement under Securities Act of 1933  
06/16/2026 3:30 PM
Lundberg Sven Ante (1682126) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:30 PM
Q32 Bio (1661998) Issuer
Xu Diyong (1995088) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:30 PM
Q32 Bio (1661998) Issuer
Thistle Mary (1317917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:30 PM
GRAYZEL DAVID S. (1732786) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:30 PM
Q32 Bio (1661998) Issuer
TZIANABOS ARTHUR (1586226) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:30 PM
Manke Isaac (1622769) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:30 PM
Iwicki Mark T (1415537) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:30 PM
LAPORTE KATHLEEN (1196201) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 3:01 PM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/08/2026 3:30 PM
Atlas Venture Associates Opportunity III, L.P. (2137711) Reporting
Atlas Venture Associates Opportunity III, LLC (2137715) Reporting
Atlas Venture Opportunity Fund Ill, L.P. (2078188) Reporting
Q32 Bio (1661998) Issuer
Form 3
Initial statement of beneficial ownership of securities  
06/04/2026 4:01 PM
Q32 Bio (1661998) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13G
06/04/2026 4:06 PM
BIOTECHNOLOGY VALUE FUND L P (918923) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13G
06/01/2026 8:10 PM
ORBIMED ADVISORS LLC (1055951) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13D/A
06/01/2026 8:13 PM
ORBIMED ADVISORS LLC (1055951) Reporting
OrbiMed Capital GP VII LLC (1760648) Reporting
OrbiMed Genesis GP LLC (1808744) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/01/2026 8:15 PM
Q32 Bio (1661998) Issuer
Xu Diyong (1995088) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 3:01 PM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Forget the million-dollar nest egg — you only need THIS much (Ad)

Nearly 2 in 3 Americans fear running out of money more than death - and chasing a $1.5 million nest egg isn't helping. Tim Plaehn has spent decades helping people build retirement income, and he says the monthly income goal is the only number that matters. His approach could potentially reach that goal with 10x less capital - using a single stock you can buy with one click.tc pixel

Watch the short presentation to see how this retirement income strategy works
05/15/2026 7:05 AM
Q32 Bio (1661998) Subject
Sirenia Capital Management LP (2115022) Filed by
Form SCHEDULE 13G
05/06/2026 4:48 PM
ORBIMED ADVISORS LLC (1055951) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13D/A
05/06/2026 3:05 PM
Opaleye Management Inc. (1595855) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13G/A
05/05/2026 6:14 AM
Q32 Bio (1661998) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/05/2026 6:04 AM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2026 6:08 AM
Q32 Bio (1661998) Filer
Form DEFA14A
04/30/2026 6:15 AM
Q32 Bio (1661998) Filer
Form ARS
04/30/2026 6:02 AM
Q32 Bio (1661998) Filer
Form DEF 14A
03/27/2026 4:13 PM
Q32 Bio (1661998) Filer
Form 424B5
03/27/2026 4:15 PM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2026 6:00 PM
Kalowski Lee (1618273) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2026 6:00 PM
Morrison Jodie Pope (1618247) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2026 6:00 PM
Q32 Bio (1661998) Issuer
Violette Shelia M. (2016144) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 4:06 PM
ORBIMED ADVISORS LLC (1055951) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13D/A
03/10/2026 6:23 AM
Q32 Bio (1661998) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/10/2026 6:05 AM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2026 6:14 AM
Q32 Bio (1661998) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/27/2026 6:00 PM
Q32 Bio (1661998) Issuer
Violette Shelia M. (2016144) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2026 6:00 PM
Morrison Jodie Pope (1618247) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2026 6:00 PM
Kalowski Lee (1618273) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 7:13 PM
Opaleye Management Inc. (1595855) Filed by
Q32 Bio (1661998) Subject
Form SCHEDULE 13G
02/17/2026 3:15 PM
Q32 Bio (1661998) Filer
Form 424B5
01/30/2026 6:00 PM
Lundberg Sven Ante (1682126) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/30/2026 6:00 PM
GRAYZEL DAVID S. (1732786) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/30/2026 6:00 PM
LAPORTE KATHLEEN (1196201) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:06 PM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/04/2025 6:00 PM
Kalowski Lee (1618273) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2025 6:00 PM
Morrison Jodie Pope (1618247) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 3:05 PM
Kalowski Lee (1618273) Reporting
Q32 Bio (1661998) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/01/2025 6:14 AM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 6:03 AM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 6:09 AM
Q32 Bio (1661998) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/27/2025 8:34 PM
Lundberg Sven Ante (1682126) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 8:19 PM
Q32 Bio (1661998) Issuer
Thistle Mary (1317917) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 8:25 PM
Q32 Bio (1661998) Issuer
Xu Diyong (1995088) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 8:26 PM
Manke Isaac (1622769) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 8:26 PM
Iwicki Mark T (1415537) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 8:16 PM
LAPORTE KATHLEEN (1196201) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 8:16 PM
Q32 Bio (1661998) Issuer
TZIANABOS ARTHUR (1586226) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 8:17 PM
GRAYZEL DAVID S. (1732786) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/21/2025 6:05 AM
Q32 Bio (1661998) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/28/2025 6:28 PM
Q32 Bio (1661998) Issuer
Violette Shelia M. (2016144) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2025 6:32 PM
Morrison Jodie Pope (1618247) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/28/2025 6:20 PM
Kalowski Lee (1618273) Reporting
Q32 Bio (1661998) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Q32 Bio SEC Filings - Frequently Asked Questions

Q32 Bio (QTTB) has submitted 404+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Q32 Bio's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Q32 Bio's financial statements page.

The most recent filing was a Form 10-Q submitted on August 5, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:QTTB) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners